Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Sorafenib

  • Yasunobu Matsuda
  • Toshifumi Wakai
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_5421-5

Synonyms

Definition

Sorafenib is a multi-kinase inhibitor that targets Raf serine/threonine kinases (C-Raf, B-Raf, and mutant B-Raf), platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptors 1 and 2 (VEGFR-1/VEGFR-2), c-Kit, and Fms-like tyrosine kinase 3 (Flt-3). Sorafenib has been proven to improve the overall survival rate of patients with unresectable hepatocellular carcinoma (HCC) and those with advanced renal cell carcinoma (RCC).

Characteristics

Chemical Name

4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methyl-2-pyridinecarboxamide

Molecular Formula

C21H16ClF3N4O3

Molecular Weight

464.825

Brand Name

Nexavar (Bayer/Onyx Pharmaceuticals). Nexavar is the tosylate salt of sorafenib with a molecular formula of C21H16ClF3N4O3 × C7H8O3S and a molecular weight of 637.0.

Therapeutic Range

Sorafenib is the only...

Keywords

Renal Cell Carcinoma Endoplasmic Reticulum Stress Zoledronic Acid Advanced Renal Cell Carcinoma Unresectable Hepatocellular Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34PubMedCrossRefGoogle Scholar
  2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRefGoogle Scholar
  3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Medical TechnologyNiigata University Graduate of Health SciencesNiigataJapan
  2. 2.Division of Digestive and General SurgeryNiigata University Graduate School of Medical and Dental SciencesNiigataJapan